Exploring modified chitosan-based gene delivery technologies for therapeutic advancements

Gholap, Amol D.; Kapare, Harshad S.; Pagar, Sakshi; Kamandar, Pallavi; Bhowmik, Deblina; Vishwakarma, Nikhar; Raikwar, Sarjana; Garkal, Atul; Mehta, Tejal A.; Rojekar, Satish; Hatvate, Navnath; Mohanto, Sourav

doi:10.1016/j.ijbiomac.2024.129581

Cited by 11 publications

(1 citation statement)

References 283 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macular degeneration, scientifically termed AMD, is a pathological condition characterized by potential visual impairment, including blurred or absent central vision [220,221]. The initial stages of the condition typically manifest without apparent symptoms [222].…”

Section: Age-related Macular Degenerationmentioning

confidence: 99%

Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery

Rojekar,

Parit,

Gholap

et al. 2024

Preprint

View full text Add to dashboard Cite

Microneedle technology is a novel platform technology that revolutionizes ocular drug delivery and addresses critical challenges in the treatment of ocular diseases. Routine treatment methods, such as eye drops and intravitreal injections, suffer from low bioavailability and poor patient compliance. So, novel advanced platform technologies are required to overcome these challenges. Microneedle is a minimally invasive and promising alternative technique that helps precisely control drug delivery to targeted tissues and organs. This review investigates the potential impact of microneedle technology for eye care, underscoring recent advancements, underlying mechanisms, and emerging preclinical and clinical uses. Different types of microneedles, including solid, coated, dissolvable, and hollow, have demonstrated their potential and capability to bypass several barriers in the cornea and sclera. This ensures effective drug penetration and delivery. The current innovations in material science and fabrication methods have enhanced the safety and efficacy of microneedles, reducing discomfort and the chances of infections. These microneedle technologies offer sustained and controlled drug delivery, which could improve therapeutic outcomes for various disease conditions like age-related macular degeneration, glaucoma, diabetic neuropathy, etc. In the current review, recent preclinical and clinical studies emphasize microneedle-based ocular drug delivery's feasibility and potential benefits. These include improved pharmacokinetics, reduced dosing frequency, enhanced patient adherence, and, most importantly, microneedles offer versatile platforms for delivering a wide range of small and large molecules and gene therapies. Despite the exciting progress, obstacles such as regulatory barriers, scalability, and long-term biocompatibility persist. It will be essential to tackle these challenges through interdisciplinary research and partnerships to integrate microneedle technology into standard clinical use effectively. Ultimately, microneedle drug delivery offers a revolutionary method that has the potential to significantly enhance the treatment and results of ocular diseases, marking the dawn of a new era in eye care.

show abstract

Section: Age-related Macular Degenerationmentioning

confidence: 99%

Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery

Rojekar,

Parit,

Gholap

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Gholap,

Khuspe,

Pardeshi

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Host‐directed therapies (HDTs) have emerged as a promising strategy to combat viral infections by modifying host factors and immune responses to restrict viral replication and improve patient outcomes. This review summarizes the latest advances and future potential of HDTs in antiviral therapy. With developments in genomics and proteomics, new host targets essential for viral replication have been identified. Gene‐editing tools, such as CRISPR‐Cas9, enable precise manipulation of host genes linked to viral processes, paving the way for innovative HDTs. Emerging approaches, including RNA interference and viral interference, further demonstrate the potential to specifically modify host factors to inhibit viral replication. Additionally, probiotics are being explored for their capacity to enhance immune responses and modulate gut microbiota, offering a natural and safe method for boosting antiviral defenses. Despite these advancements, significant challenges remain, particularly in deciphering complex host–virus interactions and ensuring the safety and efficacy of these therapies. Continued research and clinical evaluation are essential to realize the full potential of HDTs. This review provides a comprehensive overview of current HDT strategies, emphasizing their promise in shaping future antiviral interventions.

show abstract